{
    "name": "ustekinumab",
    "comment": "Rx",
    "other_names": [
        "Stelara"
    ],
    "classes": [
        "Antipsoriatics",
        "Systemic",
        "Monoclonal Antibodies",
        "Interleukin Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/stelara-ustekinumab-345050",
    "pregnancy": {
        "common": [
            "Pregnancy registry (1-877-311-8972) available that monitors pregnancy outcomes in women exposed to ustekinumab during pregnancy",
            "Limited data on ustekinumab use in pregnant women to inform a drug associated risk",
            "In animal reproductive and developmental toxicity studies, no adverse developmental effects were observed after administration of ustekinumab to pregnant monkeys at exposures greater than 100 times the human exposure at the maximum recommended human subcutaneous dose (MRHD)"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Data are not available on the presence of ustekinumab in human milk, effects on the breastfed infant, or effects on milk production",
            "Developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ustekinumab and any potential adverse effects on the breastfed child from ustekinumab or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Active serious infection",
                "Concomitant live vaccines"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Use caution in patients genetically deficient in IL-12/IL-23",
                "Reversible posterior leukoencephalopathy syndrome (RPLS); is a neurological disorder, not caused by demyelination or a known infectious agent; RPLS can present with headache, seizures, confusion, and visual disturbances; conditions with which it has been associated include preeclampsia, eclampsia, acute, hypertension, cytotoxic agents and immunosuppressive therapy; fatal outcomes reported; cases reported in postmarketing experience in patients with psoriasis, psoriatic arthritis, and Crohn’s disease; if RPLS is suspected, administer appropriate therapy and discontinue treatment",
                "Provide age-appropriate immunization prior to initiating therapy",
                "Hypersensitivity reactions reported, including anaphylaxis and angioedema"
            ],
            "specific": [
                {
                    "type": "Infections",
                    "description": [
                        "Do not administer treatment to patients with active tuberculosis infection; initiate treatment of latent tuberculosis (TB) prior to administering ustekinumab; closely monitor for signs and symptoms of active tuberculosis during and after treatment",
                        "May increase risk of infections and reactivation of latent infections; serious bacterial, fungal, mycobacterial, and viral infections observed with treatment; evaluate for TB infection before initiating drug",
                        "Cases of interstitial pneumonia, eosinophilic pneumonia and cryptogenic organizing pneumonia have been reported; if diagnosis is confirmed, discontinue therapy and institute appropriate treatment",
                        "Other serious infections requiring hospitalization reported include diverticulitis, cellulitis, pneumonia, appendicitis, cholecystitis, sepsis, osteomyelitis, viral infections, and UTIs",
                        "Do not initiate in patients with any clinically important active infection until infection resolves or is adequately treated; consider risks and benefits of treatment before initiating therapy in patients with a chronic infection or a history of recurrent infection",
                        "Instruct patients to seek medical advice if signs or symptoms suggestive of infection occur and consider discontinuing therapy for serious or clinically significant infections until infection resolves or is adequately treated",
                        "Infections observed by disease treated",
                        "Serious infections requiring hospitalization, or otherwise clinically significant infections, reported in clinical studies included the following",
                        "Psoriasis: Diverticulitis, cellulitis, pneumonia, appendicitis, cholecystitis, sepsis, osteomyelitis, viral infections, gastroenteritis, and urinary tract infections",
                        "Psoriatic arthritis: Cholecystitis",
                        "Crohn disease: Anal abscess, gastroenteritis, ophthalmic herpes zoster, pneumonia, and listeria meningitis",
                        "Ulcerative colitis: Gastroenteritis, ophthalmic herpes zoster, pneumonia, and listeriosis"
                    ]
                },
                {
                    "type": "Malignancies",
                    "description": [
                        "Increased risk of malignancy",
                        "Reports of the rapid appearance of multiple cutaneous squamous cell carcinomas in patients with pre-existing risk factors for developing nonmelanoma skin cancer; monitor all patients for nonmelanoma skin cancer"
                    ]
                },
                {
                    "type": "Drug interactions overview",
                    "description": [
                        "Formation of CYP450 enzymes can be altered by increased levels of certain cytokines (eg, IL-1, IL-6, IL-10, TNFα, IFN) during chronic inflammation; ustekinumab (IL-12 and IL-23 antagonist) may normalize the formation of CYP450 enzyme; monitor therapeutic effects (eg, warfarin) or concentration (eg, cyclosporine) with concomitant CYP450 substrates use (especially narrow therapeutic index drugs)",
                        "Psoriasis studies the safety of ustekinumab in combination with immunosuppressive agents or phototherapy has not been evaluated; in psoriatic arthritis studies, concomitant methotrexate use did not appear to influence the safety or efficacy",
                        "May decrease the protective effect of allergen immunotherapy",
                        "Avoid use of live vaccines with ustekinumab",
                        "BCG vaccines should not be given during treatment or for one year prior to initiating treatment or one year following discontinuation of treatment; use caution when administering live vaccines to household contacts of patients receiving treatment due to the potential risk for shedding from the household contact and transmission to patient"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "adenovirus types 4 and 7 live, oral",
            "description": {
                "common": "ustekinumab decreases effects of adenovirus types 4 and 7 live, oral by Mechanism: pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "influenza virus vaccine quadrivalent, adjuvanted",
            "description": {
                "common": "ustekinumab decreases effects of influenza virus vaccine quadrivalent, adjuvanted by pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "influenza virus vaccine quadrivalent, intranasal",
            "description": {
                "common": "ustekinumab decreases effects of influenza virus vaccine quadrivalent, intranasal by Mechanism: pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "influenza virus vaccine quadrivalent, recombinant",
            "description": {
                "common": "ustekinumab decreases effects of influenza virus vaccine quadrivalent, recombinant by pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "influenza virus vaccine trivalent, adjuvanted",
            "description": {
                "common": "ustekinumab decreases effects of influenza virus vaccine trivalent, adjuvanted by pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "influenza virus vaccine trivalent, recombinant",
            "description": {
                "common": "ustekinumab decreases effects of influenza virus vaccine trivalent, recombinant by pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "measles (rubeola) vaccine",
            "description": {
                "common": "ustekinumab decreases effects of measles (rubeola) vaccine by Mechanism: pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "measles mumps and rubella vaccine, live",
            "description": {
                "common": "ustekinumab decreases effects of measles mumps and rubella vaccine, live by Mechanism: pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "rotavirus oral vaccine, live",
            "description": {
                "common": "ustekinumab decreases effects of rotavirus oral vaccine, live by Mechanism: pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "rubella vaccine",
            "description": {
                "common": "ustekinumab decreases effects of rubella vaccine by Mechanism: pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "smallpox (vaccinia) vaccine, live",
            "description": {
                "common": "ustekinumab decreases effects of smallpox (vaccinia) vaccine, live by Mechanism: pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "varicella virus vaccine live",
            "description": {
                "common": "ustekinumab decreases effects of varicella virus vaccine live by Mechanism: pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "yellow fever vaccine",
            "description": {
                "common": "ustekinumab decreases effects of yellow fever vaccine by Mechanism: pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "zoster vaccine live",
            "description": {
                "common": "ustekinumab decreases effects of zoster vaccine live by Mechanism: pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "adalimumab",
            "description": {
                "common": "adalimumab and ustekinumab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "adenovirus types 4 and 7 live, oral",
            "description": {
                "common": "ustekinumab decreases effects of adenovirus types 4 and 7 live, oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3mo after cessation of immunosuppressive therapy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "alefacept",
            "description": {
                "common": "alefacept and ustekinumab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "anakinra",
            "description": {
                "common": "anakinra and ustekinumab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "anthrax vaccine",
            "description": {
                "common": "ustekinumab decreases effects of anthrax vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "antithymocyte globulin equine",
            "description": {
                "common": "antithymocyte globulin equine and ustekinumab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "antithymocyte globulin rabbit",
            "description": {
                "common": "antithymocyte globulin rabbit and ustekinumab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "ustekinumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "azathioprine",
            "description": {
                "common": "azathioprine and ustekinumab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "basiliximab",
            "description": {
                "common": "basiliximab and ustekinumab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "BCG vaccine live",
            "description": {
                "common": "ustekinumab decreases effects of BCG vaccine live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines. BCG vaccines should not be given during ustekinumab treatment,   for one year prior to initiating treatment, or one year following discontinuation of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "ustekinumab, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "canakinumab",
            "description": {
                "common": "canakinumab and ustekinumab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "ustekinumab, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "cyclosporine and ustekinumab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "diphtheria & tetanus toxoids",
            "description": {
                "common": "ustekinumab decreases effects of diphtheria & tetanus toxoids by pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "diphtheria & tetanus toxoids/ acellular pertussis vaccine",
            "description": {
                "common": "ustekinumab decreases effects of diphtheria & tetanus toxoids/ acellular pertussis vaccine by pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "diphtheria & tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccine",
            "description": {
                "common": "ustekinumab decreases effects of diphtheria & tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccine by pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "etanercept",
            "description": {
                "common": "etanercept and ustekinumab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "everolimus",
            "description": {
                "common": "everolimus and ustekinumab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "glatiramer",
            "description": {
                "common": "glatiramer and ustekinumab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "golimumab",
            "description": {
                "common": "golimumab and ustekinumab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hepatitis b vaccine",
            "description": {
                "common": "ustekinumab decreases effects of hepatitis b vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydroxychloroquine sulfate",
            "description": {
                "common": "hydroxychloroquine sulfate and ustekinumab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "ustekinumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "infliximab",
            "description": {
                "common": "infliximab and ustekinumab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "influenza virus vaccine quadrivalent, cell-cultured",
            "description": {
                "common": "ustekinumab decreases effects of influenza virus vaccine quadrivalent, cell-cultured by pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "influenza virus vaccine quadrivalent, intranasal",
            "description": {
                "common": "ustekinumab decreases effects of influenza virus vaccine quadrivalent, intranasal by pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "influenza virus vaccine trivalent",
            "description": {
                "common": "ustekinumab decreases effects of influenza virus vaccine trivalent by pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "Japanese encephalitis virus vaccine",
            "description": {
                "common": "ustekinumab decreases effects of Japanese encephalitis virus vaccine by pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "leflunomide",
            "description": {
                "common": "leflunomide and ustekinumab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "ustekinumab, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "measles (rubeola) vaccine",
            "description": {
                "common": "ustekinumab decreases effects of measles (rubeola) vaccine by pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "measles mumps and rubella vaccine, live",
            "description": {
                "common": "ustekinumab decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "measles, mumps, rubella and varicella vaccine, live",
            "description": {
                "common": "ustekinumab decreases effects of measles, mumps, rubella and varicella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "muromonab CD3",
            "description": {
                "common": "muromonab CD3 and ustekinumab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mycophenolate",
            "description": {
                "common": "mycophenolate and ustekinumab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rilonacept",
            "description": {
                "common": "rilonacept and ustekinumab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rotavirus oral vaccine, live",
            "description": {
                "common": "ustekinumab decreases effects of rotavirus oral vaccine, live by pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rubella vaccine",
            "description": {
                "common": "ustekinumab decreases effects of rubella vaccine by pharmacodynamic antagonism. Contraindicated. IPrior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sirolimus",
            "description": {
                "common": "sirolimus and ustekinumab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "smallpox (vaccinia) vaccine, live",
            "description": {
                "common": "ustekinumab decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "tacrolimus and ustekinumab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "temsirolimus",
            "description": {
                "common": "temsirolimus and ustekinumab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tetanus toxoid adsorbed or fluid",
            "description": {
                "common": "ustekinumab decreases effects of tetanus toxoid adsorbed or fluid by pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tick-borne encephalitis vaccine",
            "description": {
                "common": "ustekinumab decreases effects of tick-borne encephalitis vaccine by pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "ustekinumab, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tocilizumab",
            "description": {
                "common": "tocilizumab and ustekinumab both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tongkat ali",
            "description": {
                "common": "ustekinumab and tongkat ali both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "travelers diarrhea and cholera vaccine inactivated",
            "description": {
                "common": "ustekinumab decreases effects of travelers diarrhea and cholera vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "typhoid polysaccharide vaccine",
            "description": {
                "common": "ustekinumab decreases effects of typhoid polysaccharide vaccine by pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "typhoid vaccine live",
            "description": {
                "common": "ustekinumab decreases effects of typhoid vaccine live by pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "upadacitinib",
            "description": {
                "common": "ustekinumab, upadacitinib.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "varicella virus vaccine live",
            "description": {
                "common": "ustekinumab decreases effects of varicella virus vaccine live by pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "yellow fever vaccine",
            "description": {
                "common": "ustekinumab decreases effects of yellow fever vaccine by pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "zoster vaccine live",
            "description": {
                "common": "ustekinumab decreases effects of zoster vaccine live by pharmacodynamic antagonism. Contraindicated. Prior initiating therapy, patients should receive all  age-appropriate immunizations as recommended by current guidelines. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alfentanil",
            "description": {
                "common": "ustekinumab, alfentanil. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amphotericin B cholesteryl sulfate",
            "description": {
                "common": "ustekinumab, amphotericin B cholesteryl sulfate. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amphotericin B deoxycholate",
            "description": {
                "common": "ustekinumab, amphotericin B deoxycholate. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "astragalus",
            "description": {
                "common": "ustekinumab increases and astragalus decreases immunosuppressive effects; risk of infection. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belatacept",
            "description": {
                "common": "belatacept and ustekinumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "ustekinumab, carbamazepine. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clonidine",
            "description": {
                "common": "ustekinumab, clonidine. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "colchicine",
            "description": {
                "common": "ustekinumab, colchicine. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "ustekinumab, cyclosporine. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "denosumab",
            "description": {
                "common": "ustekinumab, denosumab. Other (see comment). Use Caution/Monitor. \nComment: Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "digoxin",
            "description": {
                "common": "ustekinumab, digoxin. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dihydroergotamine",
            "description": {
                "common": "ustekinumab, dihydroergotamine. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "disopyramide",
            "description": {
                "common": "ustekinumab, disopyramide. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "divalproex sodium",
            "description": {
                "common": "ustekinumab, divalproex sodium. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "echinacea",
            "description": {
                "common": "ustekinumab increases and echinacea decreases immunosuppressive effects; risk of infection. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efgartigimod alfa",
            "description": {
                "common": "efgartigimod alfa will decrease the level or effect of ustekinumab by  receptor binding competition. Use Caution/Monitor. Coadministration of efgartigimod with medications that bind to the human neonatal Fc receptor may lower systemic exposures and effectiveness of such medications. Closely monitor for reduced effectiveness of medications that bind to the human neonatal Fc receptor. If long-term use of such medications is essential, consider discontinuing efgartigimod and using alternative therapies."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ergotamine",
            "description": {
                "common": "ustekinumab, ergotamine. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethosuximide",
            "description": {
                "common": "ustekinumab, ethosuximide. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "everolimus",
            "description": {
                "common": "ustekinumab, everolimus. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fentanyl",
            "description": {
                "common": "ustekinumab, fentanyl. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fingolimod",
            "description": {
                "common": "ustekinumab increases effects of fingolimod by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "ustekinumab, fosphenytoin. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haemophilus influenzae type b vaccine",
            "description": {
                "common": "ustekinumab decreases effects of haemophilus influenzae type b vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hepatitis A vaccine inactivated",
            "description": {
                "common": "ustekinumab decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Use Caution/Monitor. Inactivated vaccinations administered during ustekinumab treatment may not elicit an immune response sufficient to prevent disease."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hepatitis a/b vaccine",
            "description": {
                "common": "ustekinumab decreases effects of hepatitis a/b vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Inactivated vaccinations administered during ustekinumab treatment may not elicit an immune response sufficient to prevent disease."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hepatitis a/typhoid vaccine",
            "description": {
                "common": "ustekinumab decreases effects of hepatitis a/typhoid vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Inactivated vaccinations administered during ustekinumab treatment may not elicit an immune response sufficient to prevent disease."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "human papillomavirus vaccine, nonavalent",
            "description": {
                "common": "ustekinumab decreases effects of human papillomavirus vaccine, nonavalent by pharmacodynamic antagonism. Use Caution/Monitor. Inactivated vaccinations administered during ustekinumab treatment may not elicit an immune response sufficient to prevent disease."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "human papillomavirus vaccine, quadrivalent",
            "description": {
                "common": "ustekinumab decreases effects of human papillomavirus vaccine, quadrivalent by pharmacodynamic antagonism. Use Caution/Monitor. Inactivated vaccinations administered during ustekinumab treatment may not elicit an immune response sufficient to prevent disease."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydroxyurea",
            "description": {
                "common": "hydroxyurea, ustekinumab. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of infection."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "ifosfamide, ustekinumab.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "irinotecan",
            "description": {
                "common": "ustekinumab, irinotecan. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "ustekinumab and isavuconazonium sulfate both decrease  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levothyroxine",
            "description": {
                "common": "ustekinumab, levothyroxine. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lithium",
            "description": {
                "common": "ustekinumab, lithium. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lomustine",
            "description": {
                "common": "lomustine and ustekinumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maitake",
            "description": {
                "common": "ustekinumab increases and maitake decreases immunosuppressive effects; risk of infection. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mechlorethamine",
            "description": {
                "common": "mechlorethamine, ustekinumab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mercaptopurine",
            "description": {
                "common": "mercaptopurine and ustekinumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methotrexate",
            "description": {
                "common": "methotrexate and ustekinumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam",
            "description": {
                "common": "ustekinumab, midazolam. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "minoxidil",
            "description": {
                "common": "ustekinumab, minoxidil. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofatumumab SC",
            "description": {
                "common": "ofatumumab SC, ustekinumab.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olaparib",
            "description": {
                "common": "ustekinumab and olaparib both increase  pharmacodynamic synergism. Use Caution/Monitor. Coadministration with other other myelosuppressive anticancer agents, including DNA damaging agents,  may potentiate and prolongate the myelosuppressive toxicity. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "oxaliplatin and ustekinumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Use of oxaliplatin with concomitant immunosuppressants or with impaired immune systems may increased risk for serious infections."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "ustekinumab, phenobarbital. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "ustekinumab, phenytoin. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pneumococcal vaccine 13-valent",
            "description": {
                "common": "ustekinumab decreases effects of pneumococcal vaccine 13-valent by pharmacodynamic antagonism. Use Caution/Monitor. Inactivated vaccinations administered during ustekinumab treatment may not elicit an immune response sufficient to prevent disease."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pneumococcal vaccine heptavalent",
            "description": {
                "common": "ustekinumab decreases effects of pneumococcal vaccine heptavalent by pharmacodynamic antagonism. Use Caution/Monitor. Inactivated vaccinations administered during ustekinumab treatment may not elicit an immune response sufficient to prevent disease."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pneumococcal vaccine polyvalent",
            "description": {
                "common": "ustekinumab decreases effects of pneumococcal vaccine polyvalent by pharmacodynamic antagonism. Use Caution/Monitor. Inactivated vaccinations administered during ustekinumab treatment may not elicit an immune response sufficient to prevent disease."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "poliovirus vaccine inactivated",
            "description": {
                "common": "ustekinumab decreases effects of poliovirus vaccine inactivated by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prazosin",
            "description": {
                "common": "ustekinumab, prazosin. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primidone",
            "description": {
                "common": "ustekinumab, primidone. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "procainamide",
            "description": {
                "common": "ustekinumab, procainamide. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinidine",
            "description": {
                "common": "ustekinumab, quinidine. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinine",
            "description": {
                "common": "ustekinumab, quinine. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rabies vaccine",
            "description": {
                "common": "ustekinumab decreases effects of rabies vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Inactivated vaccinations administered during ustekinumab treatment may not elicit an immune response sufficient to prevent disease."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rabies vaccine chick embryo cell derived",
            "description": {
                "common": "ustekinumab decreases effects of rabies vaccine chick embryo cell derived by pharmacodynamic antagonism. Use Caution/Monitor. Inactivated vaccinations administered during ustekinumab treatment may not elicit an immune response sufficient to prevent disease."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sipuleucel-T",
            "description": {
                "common": "ustekinumab decreases effects of sipuleucel-T by pharmacodynamic antagonism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sirolimus",
            "description": {
                "common": "ustekinumab, sirolimus. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "ustekinumab, tacrolimus. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "temsirolimus",
            "description": {
                "common": "ustekinumab, temsirolimus. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "theophylline",
            "description": {
                "common": "ustekinumab, theophylline. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thioridazine",
            "description": {
                "common": "ustekinumab, thioridazine. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "topotecan",
            "description": {
                "common": "ustekinumab, topotecan. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab",
            "description": {
                "common": "trastuzumab, ustekinumab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab deruxtecan",
            "description": {
                "common": "trastuzumab deruxtecan, ustekinumab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab and ustekinumab both increase  immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministered"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valproic acid",
            "description": {
                "common": "ustekinumab, valproic acid. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zoster vaccine recombinant",
            "description": {
                "common": "ustekinumab decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Upper respiratory infection",
            "percent": null
        },
        {
            "name": "Nasopharyngitis",
            "percent": null
        },
        {
            "name": "Back pain",
            "percent": null
        },
        {
            "name": "Cellulitis",
            "percent": null
        },
        {
            "name": "Depression",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Injection site erythema",
            "percent": null
        },
        {
            "name": "Myalgia",
            "percent": null
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "Nasal congestion",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Antibody formation",
            "percent": null
        },
        {
            "name": "Severe infection",
            "percent": null
        },
        {
            "name": "Malignancy",
            "percent": null
        },
        {
            "name": "Reversible posterior leukoencephalopathy syndrome",
            "percent": null
        },
        {
            "name": "Immune system disorders",
            "percent": null
        },
        {
            "name": "Serious hypersensitivity reactions",
            "percent": null
        },
        {
            "name": "including anaphylaxis and angioedema",
            "percent": null
        },
        {
            "name": "other hypersensitivity reactions",
            "percent": null
        },
        {
            "name": "including rash and urticaria",
            "percent": null
        },
        {
            "name": "Skin reactions",
            "percent": null
        },
        {
            "name": "Pustular psoriasis",
            "percent": null
        },
        {
            "name": "erythrodermic psoriasis",
            "percent": null
        },
        {
            "name": "hypersensitivity vasculitis",
            "percent": null
        },
        {
            "name": "Respiratory",
            "percent": null
        },
        {
            "name": "thoracic and mediastinal disorders",
            "percent": null
        },
        {
            "name": "Lower respiratory tract infection",
            "percent": null
        },
        {
            "name": "interstitial pneumonia",
            "percent": null
        },
        {
            "name": "eosinophilic pneumonia and cryptogenic organizing pneumonia",
            "percent": null
        }
    ]
}